These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 19930057)
1. ProFESS trial: any lessons to learn for future anti-platelet trials? Sharma JC; Vassallo M; Ross IN Int J Stroke; 2009 Dec; 4(6):458-60. PubMed ID: 19930057 [No Abstract] [Full Text] [Related]
2. [Platelet-function inhibitors in the secondary prevention of ischemic stroke]. Busse O; Diener HC; Grond M Dtsch Med Wochenschr; 2006 Nov; 131 Suppl 5():S132-4. PubMed ID: 17089258 [No Abstract] [Full Text] [Related]
5. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention. Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182 [No Abstract] [Full Text] [Related]
6. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy. Biller J J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related]
8. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?]. Diener C MMW Fortschr Med; 2008 May; 150(21):7. PubMed ID: 18578065 [No Abstract] [Full Text] [Related]
9. Newer antiplatelet therapies in stroke prevention. Davis SM; Donnan GA Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112 [TBL] [Abstract][Full Text] [Related]
10. The PRoFESS trial results: what went wrong? Anderson CS Int J Stroke; 2008 Aug; 3(3):165-6. PubMed ID: 18705892 [No Abstract] [Full Text] [Related]
11. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. Kirshner HS Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet agents and randomized trials. Diener HC Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669 [TBL] [Abstract][Full Text] [Related]
13. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice. Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714 [No Abstract] [Full Text] [Related]
14. [ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?]. Einecke D MMW Fortschr Med; 2008 May; 150(21):6-7. PubMed ID: 18575244 [No Abstract] [Full Text] [Related]
15. Medications used to prevent adhesion and clotting. Lassiter TF Lippincotts Prim Care Pract; 2000; 4(6):619-32; quiz 633-5. PubMed ID: 11933375 [No Abstract] [Full Text] [Related]
16. [Clopidogrel protection is not increased further by ASS!]. Bogousslavsky J Praxis (Bern 1994); 2004 Aug; 93(35):1390. PubMed ID: 15468578 [No Abstract] [Full Text] [Related]
17. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? Diener HC Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062 [TBL] [Abstract][Full Text] [Related]
20. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view. Gebel JM J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]